Patents by Inventor Edwin Kets

Edwin Kets has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175902
    Abstract: The present invention relates to a liquid composition of live Mollicutes bacteria and a stabiliser, whereby the stabiliser is a natural deep-eutectic solvent (NADES). In this liquid composition the live Mollicutes are stabilised without need for freezing or freeze-drying. This allows various advantageous uses in diagnostics and medicine, specifically as a liquid vaccine for use against infection or disease caused by Mollicutes bacteria, for human- or non-human animals.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Applicant: Intervet Inc.
    Inventors: Martin Piest, Edwin Kets, Paul Vermeij, Marian Anna Catharina Jozefina Huijnen, Noel Dautzenberg
  • Patent number: 11344617
    Abstract: The present invention describes a liquid vaccine composition of a live enveloped virus and a pharmaceutically acceptable carrier, whereby the carrier is a natural deep-eutectic solvent (NADES), and the vaccine has a water activity of less than about 0.8. The NADES provides a stabilisation of the sensitive virus for prolonged time and at ambient temperature. In general, the liquid vaccine compositions according to the invention, in different compositions for the various enveloped viruses, show remarkable capabilities of stabilisation. This overcomes the need for lyophilisation, a great economic benefit. Also the liquid nature of the vaccines facilitates administration to human or animal targets.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 31, 2022
    Assignee: Intervet Inc.
    Inventors: Paul Vermeij, Edwin Kets, Chris Dirks, Martin Piest
  • Publication number: 20200368346
    Abstract: The present invention describes a liquid vaccine composition of a live enveloped virus and a pharmaceutically acceptable carrier, whereby the carrier is a natural deep-eutectic solvent (NADES), and the vaccine has a water activity of less than about 0.8. The NADES provides a stabilisation of the sensitive virus for prolonged time and at ambient temperature. In general, the liquid vaccine compositions according to the invention, in different compositions for the various enveloped viruses, show remarkable capabilities of stabilisation. This overcomes the need for lyophilisation, a great economic benefit. Also the liquid nature of the vaccines facilitates administration to human or animal targets.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 26, 2020
    Applicant: Intervet Inc.
    Inventors: Paul Vermeij, Edwin Kets, Chris Dirks, Martin Piest
  • Patent number: 10046038
    Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 14, 2018
    Assignee: Intervet Inc.
    Inventors: Christian Theodoor Gerardus Smits, Edwin Kets, Henriette Adriaanse
  • Publication number: 20150306199
    Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.
    Type: Application
    Filed: December 20, 2013
    Publication date: October 29, 2015
    Applicant: Intervet Inc.
    Inventors: Christian Theodoor Gerardus Smits, Edwin Kets, Henriette Adriaanse
  • Publication number: 20140178433
    Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific fatty acid: linoleic acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.
    Type: Application
    Filed: December 16, 2013
    Publication date: June 26, 2014
    Inventors: Edwin Kets, Christian Theodoor Gerardus Smits, Henriette Adriaanse